Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Nanology
- 16 Oct 2017 According to a Nanology media release, first patient has been enrolled.
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.
- 15 Mar 2017 New trial record